Novartis AG (FRA:NOT) Piotroski F-Score: 5 (As of Jun. 24, 2026) — 17% Below Median


FRA:NOT Novartis AG FRA:NOT
83 GF Score
Price €131.52
GF Value €109.77
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis AG Piotroski F-Score?

Novartis AG FRA:NOT +2.14% 83 Piotroski F-Score is 5 as of Jun. 24, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates FRA:NOT with a GF Score™ of 83/100 and a GF Value™ of €109.77 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Novartis AG ranks better than 61.26% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis AG has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Novartis AG's Piotroski F-Score or its related term are showing as below:

FRA:NOT' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Novartis AG was 8. The lowest was 5. And the median was 6.

Novartis AG  (FRA:NOT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Novartis AG Piotroski F-Score Related Terms


Novartis AG Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Novartis AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Piotroski F-Score Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 7.00 7.00 7.00

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 7.00 7.00 5.00

FRA:NOT vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Novartis AG's Piotroski F-Score falls into.


FRA:NOT
83GF Score
Novartis AG FRA:NOT
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 3503.547 + 3346.656 + 2057.286 + 2729.94 = €11,637 Mil.
Cash Flow from Operations was 5777.688 + 5598.492 + 1933.456 + 3179.74 = €16,489 Mil.
Revenue was 12862.812 + 12233.016 + 11836.44 + 11698.26 = €48,631 Mil.
Gross Profit was 9982.638 + 9217.788 + 8752.646 + 8706.225 = €36,659 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(92445.425 + 90510.465 + 91410.228 + 94750.446 + 102530.18) / 5 = €94329.3488 Mil.
Total Assets at the begining of this year (Mar25) was €92,445 Mil.
Long-Term Debt & Capital Lease Obligation was €33,830 Mil.
Total Current Assets was €23,015 Mil.
Total Current Liabilities was €27,139 Mil.
Net Income was 3015.534 + 2873.289 + 2691.19 + 3335.55 = €11,916 Mil.

Revenue was 11958.088 + 11867.972 + 12947.89 + 12598.5 = €49,372 Mil.
Gross Profit was 9010.371 + 8954.138 + 9773.47 + 9613.525 = €37,352 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(86787.28 + 90582.145 + 93275.124 + 97644.93 + 92445.425) / 5 = €92146.9808 Mil.
Total Assets at the begining of last year (Mar24) was €86,787 Mil.
Long-Term Debt & Capital Lease Obligation was €21,485 Mil.
Total Current Assets was €23,225 Mil.
Total Current Liabilities was €29,248 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis AG's current Net Income (TTM) was 11,637. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis AG's current Cash Flow from Operations (TTM) was 16,489. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=11637.429/92445.425
=0.12588431

ROA (Last Year)=Net Income/Total Assets (Mar24)
=11915.563/86787.28
=0.13729619

Novartis AG's return on assets of this year was 0.12588431. Novartis AG's return on assets of last year was 0.13729619. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Novartis AG's current Net Income (TTM) was 11,637. Novartis AG's current Cash Flow from Operations (TTM) was 16,489. ==> 16,489 > 11,637 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=33830.15/94329.3488
=0.35863865

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=21484.975/92146.9808
=0.23315984

Novartis AG's gearing of this year was 0.35863865. Novartis AG's gearing of last year was 0.23315984. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=23015.055/27138.51
=0.8480589

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=23224.9/29247.575
=0.79407951

Novartis AG's current ratio of this year was 0.8480589. Novartis AG's current ratio of last year was 0.79407951. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Novartis AG's number of shares in issue this year was 1916. Novartis AG's number of shares in issue last year was 1979. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=36659.297/48630.528
=0.753833

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=37351.504/49372.45
=0.75652523

Novartis AG's gross margin of this year was 0.753833. Novartis AG's gross margin of last year was 0.75652523. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=48630.528/92445.425
=0.5260458

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=49372.45/86787.28
=0.56889039

Novartis AG's asset turnover of this year was 0.5260458. Novartis AG's asset turnover of last year was 0.56889039. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis AG has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Novartis AG (FRA:NOT) has a Piotroski F-Score of 5 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Novartis AG and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Novartis AG's Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, Novartis AG ranks #380 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.7%.
Is Novartis AG's Piotroski F-Score too high?
Novartis AG's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Novartis AG's value of 5 is 0% at this industry median. Based on the distribution chart, Novartis AG ranks #380 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #380 out of 981 companies for Piotroski F-Score. This puts Novartis AG in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Novartis AG's value of 5 is 0% at this benchmark. Historically, Novartis AG's own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Novartis AG has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis AG's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €109.77, compared to a current price of €131.52 — trading 19.8% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Novartis AG's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Novartis AG (FRA:NOT), the current Piotroski F-Score is 5 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €131.52 is trading 19.8% above its estimated GF Value™ of €109.77. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: €109.77 vs. price of €131.52 (19.8% above fair value)
  • GF Score™: 83/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#380 of 981)

No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.52
Price
€109.77
GF Value